PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance

Core Insights - PharmAla Biotech Holdings Inc. has contracted with a UK-based CDMO for the manufacture of its ALA-002 drug substance, marking a significant step towards executing its Phase 2 clinical trial in 2026 [1][2] - ALA-002 is a patented, novel, non-racemic MDMA formulation aimed at treating Social Anxiety Disorder, with clinical research set to begin in 2026 [2] - The company has completed one of two shipments of LaNeo MDMA to the Parsons Research Center for Psychedelic Healing at Mount Sinai for clinical research purposes [3] Company Overview - PharmAla Biotech Holdings Inc. focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the global backlog of clinical-grade MDMA for trials and commercial sales [4] - The company is recognized as the only provider of clinical-grade MDMA for patient treatments outside of clinical trials, emphasizing its commitment to regulatory relationships [4] - PharmAla's research and development unit has completed proof-of-concept research into several intellectual property families, including ALA-002, its lead drug candidate [4]